Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF1K16 in Patients With Refractory Solid Tumors
NCT05388487Phase 1Recruiting
- Sponsor
- HighField Biopharmaceuticals
- Start
- Feb 2022
- Primary completion
- Apr 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of HF1K16 in solid tumor and glioma (5 cohorts), sponsored by HighField Biopharmaceuticals. Primary endpoints: Incidence of Adverse Events, Incidence of dose-limiting toxicities (DLT) and 9 more. Started Feb 2022; status: recruiting.
02
Drugs
HF1K16
03
Conditions
solid tumorglioma
Beyond the preview
Go deeper on NCT05388487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388487.